# Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults

> **NCT07249463** · PHASE2 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 96 (estimated)

## Conditions studied

- Cryptosporidiosis

## Interventions

- **BIOLOGICAL:** Cryptosporidium parvum oocysts (ABO809)
- **DRUG:** EDI048
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07249463
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-08
- **Primary completion:** 2027-03-02
- **Final completion:** 2027-03-02
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07249463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07249463, "Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07249463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*